Biotech Investing: A List of Stem Cell Stocks from “A” to “Z”

Biotech investing has become an increasingly popular in recent years. Whether you’re new to biotech stocks or you’ve been around the block, with the recent stock market drops caused by COVID-19, now could be a good time to place your bets.

The stock market had its largest point drop in recent history on March 9, 2020. Shortly thereafter, on March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered somewhat following the $2.2 trillion stimulus bill, market prices remain attractive across many sectors.

Furthermore, stem cell companies are receiving startling support for use of living therapeutics against COVID-19 induced respiratory complications, such as ARDS. The Australian company, Mesoblast, is now enrolling for a 300 person trial and the American company, Athersys, is enrolling for an even larger 400 person trial.

Under these conditions, one of the most intriguing niches within biotech investing is stem cell stocks.

What Are Stem Cells?

Stem cells are undifferentiated cells that have the capacity to both differentiate and multiply into the 200 cells types that form a human being.

In total, the human body is composed of an estimated 30 trillion cells, making stem cells extremely important to human development. Stem cells are also found in plants and animals.

Stem cells are the master cells in your body, and they can multiply in one of two ways.

First, they can form more stem cells like themselves. Second, they can differentiate into specialized cell types, such as muscles cells, bloods cells, or brain cells, for example.

Stem Cell Stocks for 2020

Below is an list of all publicly traded stem cell stocks, listed alphabetically by their ticker symbol from “A” to “Z.” As you can see, there are over 30 publicly traded stem cell stocks for you to consider.

ADR-Autolus Therapeutics-NASDAQ

Autolus Therapeutics focuses on T-cell therapies for cancer patients.

ALPMY-Astellas Pharma-NASDAQ

Astellas is a biotech company dealing with cancer, specifically bladder cancer. They also import, export, and develop pharmaceutical products.

ATHX-Athersys-NASDAQ

Arthersys is hoping to treat ischemic stroke, neurological disease, cardiovascular problems, and immune and inflammatory diseases.

BCDA-Biocardia-NASDAQ

Biocardia is a company that is involved with medicine for cardiovascular issues.

BCLI-BrainStorm Cell Therapeutics-NASDAQ

They have a wide array of products looking to fight ALS and other neurodegenerative diseases. such as MS, Huntington’s Disease, and Parkinson’s among others.

BSEM-Biostem Technologies Inc-OTC

BioStem Technologies develops amniotic membrane and umbilical cord tissue derived products for use in regenerative medicine, including: RHEO™, OROPRO™, VENDAJE™ and VENDAJE™ OPTIC.

BLUE-bluebird bio-NASDAQ

Bluebird Bio develops gene therapies.

BPSR-Organicell Regenerative Medicine Inc-OTC

Organicell is an integrated exosome therapeutics company. It is focused on ground-breaking research in the field of nanotechnology and is pursuing exosomes and other micro vesicles as the next frontier in stem cell-based therapeutics.

BRTX-BioRestorative-OTCQB

This company is developing stem cell treatments for disc degeneration in chronic back pain. They’re also looking into treating metabolic disorders.

CAPR-Capricor Therapeutics-NASDAQ

They discover, develop, and commercialize first-class therapeutics in the biological field.

CBMG-Cellular Biomedicine Group-NASDAQ

They develop immunotherapies for cancer patients and also develop stem cell therapies for degenerative problems. They’re also looking to treat osteoarthritis.

CCEL-Cryo-Cell International-OTCQB

CCEL is hoping to make advances in regenerative medicine with the cryo-preservation of stem cells. Their technology uses umbilical cord cells.

CELG-Celgene Corporation-NASDAQ

They develop and commercialize medicines for inflammatory disorders and cancer.

CLBS-Caladrius Biosciences-NASDAQ

Caladrius has three different products to treat autoimmune and cardiovascular diseases.

CYP-Cynata Therapeutics LTD-ASE

They have their own technology using mesenchymal stem cells.

CYTX-Cytori Therapeutics-NASDAQ

Cytori Therapeutics deals in specialty therapeutics combining nanoparticle and proprietary cell therapy platforms. They want to treat degenerative and oncologic conditions.

FATE-Fate Therapeutics INC.-NASDAQ

Fate Therapeutics develops programmed cellular immunotherapies.

GERN-Geron Corporation-NASDAQ

Geron develops technology dealing with hematologic myeloid malignancies. They also specialize in therapeutic oncology products.

GMDA-Gamida Cell-NASDAQ

Gamida Cell is hoping to treat rare hematologic problems as well as blood cancers. They’re also looking to help bone marrow, transplant patients.

KDST-Kadimastem-IT

Kadimastem is a biotech company that commercializes and develops embryonic stem cell products.

KOOL-Cesca Therapeutics-NASAQ

Cesca Therapeutics wants to deliver automated technologies for cell-based therapeutics. They’re also engaged in immune-oncology automation and clinical biobanking.

LCTX-Lineage Cell Therapeutics-NASDAQ

This company develops novel cell therapies at the clinical level.

MDT-Medtronic-NASDAQ

Medtronic provides stem cell technology to treat a broad range of medical conditions and diseases.

MESO-Mesoblast Limited-NASDAQ

Mesoblast is focused on regenerative stell cell treatments for cardiovascular disease, back pain, and inflammatory ailments.

ORGS-Orgenesis-NASDAQ

Orgenesis develops and manufactures services in the gene and stem cell industry.

OSIR-Osirus-OTC

Osirus deals with a broad range of injuries and medical issues. Some of them include burns, bone grafts, and regeneration.

PSTI-Pluristem Therapeutics-NASDAQ

Pluristem develops placenta based off the shelf products. They are looking to treat radiation damage, ischemia, and other inflammatory problems.

RGS-Regeneus Ltd-ASX

REPCF-RepliCel-OTC

RepliCel specializes in stem cell-based approaches to hair, skin, and tendon regeneration.

SGMO-Sangamo Therapeutics-NASDAQ

Sangamo Therapeutics is a gene therapy pipeline that also focuses on gene editing

SNCA-Senica Biopharma-NASDAQ

Deals with novel treatments of unmet medical needs.

STML-Stemline Therapeutics-NASDAQ

Stemline Therapeutics is solely focused on developing technologies and treatments to attack cancer cells.

THMO-ThermoGenesis Holdings-NASDAQ

They are developing stem cell processing technologies for stem cell and gene therapy.

TIG-Tigenix-EURONEXT

This company deals with stem cell technology for immune diseases and inflammation.

TKPHF-Takeda Pharmaceuticals-OTC

The largest biopharmaceutical company in Asia.

USRM-US Stem Cell-OTC

US Stem Cell hopes to help treat and prevent a variety of degenerative diseases through ongoing research.

VCEL-Vericel-NASDAQ

Vericel is focused on tissue collection, treating burn patients, and dealing with cartilage deficiencies of the knees.

VTGN-VistaGen Therapeutics-NASDAQ

VistaGen is hoping to develop commercialized entities for stem cells of the heart, liver, blood, and cartilage.

How to Invest in Stem Cell Stocks

Investing in the stem cell market can be lucrative, risky, and volatile. That’s because it is a high-risk, high reward industry. If you play your cards right ,you can win big. But, one wrong move could also empty your pockets.

After considering your risk tolerance, you’ll be ready to identify promising companies in which to invest.

First, you will want to consider the types of stem cell products being developed, the stages of development, the IP portfolio the company has secured, and any approvals issued by regulatory bodies. Next, you’ll want to consider a company’s financials, their operational costs, and their cash on hand to weather a downturn.

These factors are particular to the biotech investing industry and deserve your attention. Once you’re done your due diligence, you’ll be ready to place your bets on specific stem cell stocks.

Biotech Investing

Are there any stem cell stocks that are missing from this list? Share them in the comments and we’ll get them added. 

*Disclaimer: Neither the author, nor any BioInformant employees, own the stocks mentioned in this article. This article does not constitute financial advice. Please consult with a qualified financial adviser or certified public accountant (CPA) prior to making any investment decisions.